Pain Clinical Trial
— MODOfficial title:
Once-Daily Oral Dose of BeneFlax to Healthy Older Adults
Verified date | June 2018 |
Source | University of Saskatchewan |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators are investigating whether the flax lignan, secoisolariciresinol
diglucoside, decreases oxidative stress and inflammation. The flax seed lignan is believed to
be broken down in the body to produce the health benefits of flax. Flax lignan is separated
from the whole flax seed as this compound is believed to have health effects. Decreasing
oxidative stress and inflammation should improve a number of the problems associated with
aging. This intervention consists of 600 milligrams of the flax lignan SDG daily or an
equivalent amount of whey protein.
The investigators are comparing lignan to a placebo (whey powder) to examine whether a
dietary intervention (i.e. flax seed containing lignan) might decrease oxidative stress and
inflammation.
Status | Completed |
Enrollment | 32 |
Est. completion date | November 2014 |
Est. primary completion date | November 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Male or female adult 60 to 80 years residing in Saskatoon. - Able to comply with study protocol. - Able to follow simple instructions. Exclusion Criteria: - Age below 60 or above 80 years at initiation of the study. - Individuals living in long term care homes. - Individuals at risk of hypotension or with symptomatic hypotension. - Fasting hypoglycemia. - Unstable diabetes, or diabetics taking insulin (note: eligible diabetic participants will undergo additional testing during the study). - Current cancer or diagnosed with cancer in the past 2 years. - Women with an immediate family history or personal history of breast cancer or ovarian cancer. - Significant liver or other gastrointestinal disorder including inflammatory bowel disease. (While constipation is the most common gastrointestinal problem in the elderly, it would not be a contraindication) - Significant kidney disorder. - Unstable or severe cardiac disease, recent myocardial infarction or stroke (either in past 6 months or significantly affecting physical mobility). - Unstable other medical disease including, but not limited to, pulmonary disorder, epilepsy and genitourinary disorder. - Migraine with aura within the last year (as this is a risk factor for stroke). - Current diagnosis of a bleeding condition, or at risk of bleeding. - Significant immunocompromise. - Other unstable conditions. - Current use of hormone replacement therapy (except thyroid medication is allowed). - Current use of warfarin, clopidogrel, ticlopidine, dipyridamole or their analogues. - Intolerances or allergies to flax or vitamin D. - Allergy to whey - Surgery within the last six months. - Participation in any other clinical trial with an investigational agent within one month prior to randomization. |
Country | Name | City | State |
---|---|---|---|
Canada | Saskatoon Centre for Patient-Oriented Research | Saskatoon | Saskatchewan |
Lead Sponsor | Collaborator |
---|---|
University of Saskatchewan | Saskatchewan Health Research Foundation |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety of consumption of 600 mg/day of the flax lignan secoisolariciresinol diglucoside (SDG) in older adults (60-80 y) | Adverse event occurrences will be compared descriptively between the SDG and placebo groups. Safety will be assessed at 0, 8, 16 and 24 weeks; as part of the blood collection (urea, creatinine, total bilirubin, platelets, hematocrit, haemoglobin, mean corpuscular haemoglobin, mean corpuscular volume, white blood cell count, total protein including albumin and prealbumin, total calcium, electrolytes, glucose, liver enzymes (Aspartate transaminase (AST), Alanine Aminotransferase (ALT), Alkaline phosphatase (ALP), total protein, albumin, lipids, HbA1c (for diabetic participants). Blood pressure, pulse and respiratory rate will also be monitored at these time points. | 24 weeks | |
Secondary | Effect of SDG on blood lipids | SDG and placebo groups will be compared at 0, 8, 16 and 24 weeks for changes in nonfasting levels of cholesterol, LDL, HDL, and triglycerides. | 24 weeks | |
Secondary | Effect of SDG on inflammation | SDG and placebo groups will be compared at 0, 8, 16 and 24 weeks for changes in pro-inflammatory markers (Interleukin-6 (IL-6), IL-1a, IL-1ß, 8-isoprostane, Tumor necrosis factor-a (TNF-a), C-reactive protein). | 24 weeks | |
Secondary | Effect of SDG on quality of life | SDG and placebo groups will be compared at 0, 8, 16 and 24 weeks for changes in cognitive function, pain, and physical function. | 24 weeks | |
Secondary | Effect of SDG supplement on blood levels of flax lignan metabolites | SDG and placebo groups will be compared at 0, 8, 16 and 24 weeks for changes in cognitive function, pain, and physical function. | 24 weeks | |
Secondary | Effect of SDG supplement on fecal levels of flax lignan metabolites | To further understand the pharmacology of SDG, we will analyze fecal levels of the flax cyclolinopeptides. Levels will be determined 0 and 24 weeks. | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05559255 -
Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI
|
N/A | |
Terminated |
NCT04356352 -
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
|
Phase 2/Phase 3 | |
Completed |
NCT04748367 -
Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care
|
N/A | |
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04466111 -
Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
|
||
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05868122 -
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
|
Phase 3 | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Completed |
NCT03273114 -
Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain
|
N/A | |
Enrolling by invitation |
NCT06087432 -
Is PNF Application Effective on Temporomandibular Dysfunction
|
N/A | |
Completed |
NCT05508594 -
Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001
|
Phase 2/Phase 3 | |
Recruiting |
NCT03646955 -
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03472300 -
Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
|
||
Completed |
NCT03678168 -
A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries
|
N/A | |
Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
Completed |
NCT03286543 -
Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System
|
N/A | |
Completed |
NCT02913027 -
Can We Improve the Comfort of Pelvic Exams?
|
N/A | |
Terminated |
NCT02181387 -
Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?
|
Phase 4 | |
Recruiting |
NCT06032559 -
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
|
Phase 3 | |
Active, not recruiting |
NCT03613155 -
Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care
|